Cure SMA is pleased to announce that the 2020 Virtual SMA Conference booklet is now available for download. The booklet includes important details on the Virtual SMA Conference, including: A full agenda with ...
In the midst of the ongoing Coronavirus (COVID-19) global pandemic, Cure SMA is excited to announce its new funding for the Pediatric Neuromuscular Clinical Research Network (PNCRN). In 2020, Cure SMA will provide ...
Cure SMA is proud to share with the SMA community that it has published a paper in the Orphanet Journal of Rare Diseases, titled ‘The SMA Clinical Trial Readiness Program: Creation ...
Cure SMA is excited to reunite the SMA community for the 2021 Annual SMA Conference in Austin, Texas from Thursday, June 10 – Sunday, June 13, 2021. If the unexpected circumstances of 2020 ...
Cure SMA has released the agenda and registration details for the 2020 Virtual SMA Conference, which will be held from Monday, June 8th – Friday, June 12th. We greatly look forward to virtually ...
New SPINRAZA® (nusinersen) Data Reinforce Sustained Efficacy and Longer-Term Safety Across Broad Range of SMA Patients Biogen Inc. recently announced additional data from the SPINRAZA (nusinersen) clinical development program that further demonstrate the ...
Cure SMA has been hosting the Annual SMA Conference since 1988, bringing together leading researchers, clinicians, affected individuals, and families living with SMA. The weekend has traditionally been filled with a wide variety ...
For the past two years, Cure SMA’s Summit of Strength program has brought together thousands of SMA community members for the opportunity to network and learn about the latest advances in treatment, care, ...
Scholar Rock recently reported financial results for the first quarter ending March 31, 2020, highlighting progress and upcoming milestones for its pipeline programs—include the SRK-015 program for spinal muscular atrophy (SMA). Scholar Rock ...
Genentech, a member of the Roche Group, today presented 1-year data from FIREFISH Part 2, a pivotal global study evaluating risdiplam in infants aged 1-7 months old with symptomatic Type 1 spinal ...
Navigating the recent global health crisis, Coronavirus (COVID-19), has reinforced for us the importance of understanding what the SMA community is thinking, feeling, and experiencing. This allows us to more effectively support those ...
Cure SMA has been closely monitoring news and reports of the Coronavirus (COVID-19) outbreak, allowing us to make decisions about local events and offer new resources that support the SMA community. The current ...
